drugset / Trial / NCT01444872

Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal Dysfunction

NCT01444872

Phase 1 Completed 17 enrolled Trevena Inc.
RandomizedCrossoverSingle-blind

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TRV120027 in subjects with heart failure and mild to moderate renal dysfunction.

Timeline

Start
2011-08
Primary completion
2012-05
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject TRV120027 Peptide Intravenous